Cann Global Ltd
ASX:CGB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Skandinaviska Enskilda Banken AB
STO:SEB A
|
SE |
|
G
|
Genpact Ltd
SWB:35G
|
BM |
|
N
|
NiCAN Ltd
XTSX:NICN
|
CA |
|
U
|
Umweltbank AG
SWB:UBK
|
DE |
Cann Global Ltd
Research & Development
Cann Global Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cann Global Ltd
ASX:CGB
|
Research & Development
-AU$17.8k
|
CAGR 3-Years
65%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$36.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-10%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cann Global Ltd
Glance View
Cann Global Ltd. engages in the mining exploration and evaluation. The company is headquartered in Sydney, New South Wales. The company went IPO on 2008-01-14. The Company’s divisions include Food, Hemp Cultivation, and Processing, Skincare, Medicine, and Mining division. The Food division is focused on the production and distribution of healthy and nutritious plant-based food products for discerning Australian and Asian consumers. Hemp Cultivation and Processing division includes hulling in Australia, and broad-acre industrial cannabidiol (CBD) hemp cultivation and processing in Asia where growing conditions are ideal. The Skincare division, which includes oil, serum, and a cream product all contain hemp seed oil as the primary active ingredient. The Medicine division is responsible for research into the medicinal uses of cannabis, including research into the benefits for those with auto-immune diseases. The Mining division holds bauxite assets in the South Johnstone project, Queensland (EPM 18463).
See Also
What is Cann Global Ltd's Research & Development?
Research & Development
-17.8k
AUD
Based on the financial report for Jun 30, 2022, Cann Global Ltd's Research & Development amounts to -17.8k AUD.
What is Cann Global Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
65%
Over the last year, the Research & Development growth was 96%. The average annual Research & Development growth rates for Cann Global Ltd have been 65% over the past three years .
